{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T04:57:35Z","timestamp":1773982655797,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T00:00:00Z","timestamp":1592265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ross University School of Veterinary Medicine","award":["43001-2019"],"award-info":[{"award-number":["43001-2019"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vaccines may cause non-specific effects (NSEs) on morbidity and mortality through immune-mediated mechanisms that are not explained by the prevention of the targeted disease. Much of the evidence for NSEs comes from observational studies with a high risk of bias, and there is a clear need for new data from randomized controlled trials. Recently, it was proposed that rabies vaccine has protective NSEs in people and in animals. The aim of the proposed study is to determine whether rabies vaccine reduces the incidence rate of episodes of common infectious disease syndromes in a population of veterinary students on the island of St. Kitts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The trial design is a single-site, two-arm, parallel-group, participant-blinded, randomized, placebo-controlled, two-sided comparative study, with an internal pilot study for blinded sample size re-estimation. Allocation to study arm is by block randomization stratified by sex within cohort with a 1:1 allocation ratio. The primary study outcome is the number of new weekly episodes of common infectious diseases including respiratory, diarrheal and febrile illnesses. A vaccine immunogenicity\u00a0ancillary study is planned.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Demonstration of a non-specific protective effect of rabies vaccine against unrelated respiratory, gastrointestinal and febrile illnesses would provide supportive evidence for the design of similar studies in children in populations with a high burden of these illnesses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov, ID:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03656198\">NCT03656198<\/jats:ext-link>\n                      . Registered on 24 August 2018.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-020-04467-z","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T08:02:36Z","timestamp":1592294556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-specific effects of rabies vaccine on the incidence of common infectious disease episodes: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0425-3799","authenticated-orcid":false,"given":"Darryn","family":"Knobel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christianah Ibironke","family":"Odita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Conan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marshalette","family":"Smith-Anthony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet","family":"Battice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shianne","family":"England","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradford D.","family":"Gessner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,16]]},"reference":[{"issue":"2","key":"4467_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/cid\/cit209","volume":"57","author":"KL Flanagan","year":"2013","unstructured":"Flanagan KL, van Crevel R, Curtis N, Shann F, Levy O. Heterologous (\u201cnonspecific\u201d) and sex-differential effects of vaccines: epidemiology, clinical trials, and emerging immunologic mechanisms. Clin Infect Dis. 2013;57(2):283\u20139.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"4467_CR2","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/ni.2961","volume":"15","author":"P Aaby","year":"2014","unstructured":"Aaby P, Kollmann TR, Benn CS. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol. 2014;15(10):895\u20139.","journal-title":"Nat Immunol"},{"key":"4467_CR3","first-page":"221","volume":"89","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization, April 2014 \u2013 conclusions and recommendations. Weekly Epidemiol Rep. 2014;89:221\u201336.","journal-title":"Weekly Epidemiol Rep"},{"key":"4467_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1126\/science.aay6485","volume":"366","author":"MJ Mina","year":"2019","unstructured":"Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366:599\u2013606.","journal-title":"Science"},{"key":"4467_CR5","doi-asserted-by":"publisher","first-page":"i5170","DOI":"10.1136\/bmj.i5170","volume":"355","author":"JPT Higgins","year":"2016","unstructured":"Higgins JPT, Soares-Weiser K, L\u00f3pez-L\u00f3pez JA, Kakourou A, Chaplin K, Christensen H, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170.","journal-title":"BMJ"},{"key":"4467_CR6","doi-asserted-by":"crossref","unstructured":"Pollard AJ, Finn A, Curtis N. Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch Dis Child. 2017;102(11):1077-81.","DOI":"10.1136\/archdischild-2015-310282"},{"issue":"10026","key":"4467_CR7","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(16)30081-2","volume":"387","author":"BD Gessner","year":"2016","unstructured":"Gessner BD, Wraith DC, Finn A. CNS infection safety signal of RTS,S\/AS01 and possible association with rabies vaccine. Lancet. 2016;387(10026):1376.","journal-title":"Lancet"},{"issue":"5","key":"4467_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.vaccine.2016.12.067","volume":"35","author":"BD Gessner","year":"2017","unstructured":"Gessner BD, Knobel DL, Conan A, Finn A. Could the RTS,S\/AS01 meningitis safety signal really be a protective effect of rabies vaccine? Vaccine. 2017;35(5):716\u201321.","journal-title":"Vaccine"},{"issue":"31","key":"4467_CR9","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1016\/j.vaccine.2017.05.095","volume":"35","author":"DL Knobel","year":"2017","unstructured":"Knobel DL, Arega S, Reininghaus B, Simpson GJG, Gessner BD, Stryhn H, et al. Rabies vaccine is associated with decreased all-cause mortality in dogs. Vaccine. 2017;35(31):3844\u20139.","journal-title":"Vaccine"},{"issue":"9988","key":"4467_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31\u201345.","journal-title":"Lancet"},{"issue":"1","key":"4467_CR11","first-page":"269","volume":"48","author":"JY Brossat","year":"1981","unstructured":"Brossat JY, Cerf P, Zeller H, Coulanges P. Evidence for a non-specific immunostimulating effect on anti-rabies vaccine of the Fermi type on the Klebsiella pneumoniae system \u2013 mice. Arch Inst Pasteur Madagascar. 1981;48(1):269\u201378.","journal-title":"Arch Inst Pasteur Madagascar"},{"issue":"5","key":"4467_CR12","first-page":"610","volume":"15","author":"LP Gorshunova","year":"1970","unstructured":"Gorshunova LP, Bektemirov TA, Gumennik AE, Gogbaidze GA. Non-specific defense reactions in the central nervous system following antirabies vaccination. Vopr Virusol. 1970;15(5):610\u20132.","journal-title":"Vopr Virusol"},{"issue":"23","key":"4467_CR13","doi-asserted-by":"publisher","first-page":"10908","DOI":"10.1073\/pnas.91.23.10908","volume":"91","author":"DC Hooper","year":"1994","unstructured":"Hooper DC, Pierard I, Modelska A, Otvos L, Fu ZF, Koprowski H, et al. Rabies ribonucleocapsid as an oral immunogen and immunological enhancer. Proc Natl Acad Sci. 1994;91(23):10908\u201312.","journal-title":"Proc Natl Acad Sci"},{"key":"4467_CR14","first-page":"201","volume":"16","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Rabies vaccines: WHO position paper \u2013 April 2018. Wkly Epidemiol Rec. 2018;16:201\u201320.","journal-title":"Wkly Epidemiol Rec"},{"issue":"3","key":"4467_CR15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2471\/BLT.16.173039","volume":"95","author":"JA Kessels","year":"2017","unstructured":"Kessels JA, Recuenco S, Navarro-Vela AM, Deray R, Vigilato M, Ertl H, et al. Pre-exposure rabies prophylaxis: a systematic review. Bull World Health Organ. 2017;95(3):210\u2013219C.","journal-title":"Bull World Health Organ"},{"issue":"RR-3","key":"4467_CR16","first-page":"1","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","unstructured":"Centers for Disease Control and Prevention. Human rabies prevention \u2013 United States, 2008: recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2008;57(RR-3):1\u201328.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"4467_CR17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/sim.5947","volume":"33","author":"H Zhu","year":"2013","unstructured":"Zhu H, Lakkis H. Sample size calculation for comparing two negative binomial rates. Stat Med. 2013;33:376\u201387.","journal-title":"Stat Med"},{"key":"4467_CR18","volume-title":"MKmisc: Miscellaneous functions from M. Kohl. R package version 1.6","author":"M Kohl","year":"2019","unstructured":"Kohl M. MKmisc: Miscellaneous functions from M. Kohl. R package version 1.6. 2019. http:\/\/www.stamats.de."},{"key":"4467_CR19","volume-title":"R: a language and environment for statistical computing","author":"R Core Team","year":"2019","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2019. https:\/\/www.R-project.org\/."},{"key":"4467_CR20","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/sim.3861","volume":"29","author":"T Friede","year":"2010","unstructured":"Friede T, Schmidli H. Blinded sample size reestimation with count data: method and application in multiple sclerosis. Stat Med. 2010;29:1145\u201356.","journal-title":"Stat Med"},{"issue":"4","key":"4467_CR21","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/bimj.201200189","volume":"55","author":"S Schneider","year":"2013","unstructured":"Schneider S, Schmidli H, Friede T. Blinded and unblinded internal pilot study designs for clinical trials with count data. Biom J. 2013;55(4):617\u201333.","journal-title":"Biom J"},{"key":"4467_CR22","volume-title":"blockrand: randomization for block random clinical trials. R package version 1.3","author":"G Snow","year":"2013","unstructured":"Snow G. blockrand: randomization for block random clinical trials. R package version 1.3. 2013. https:\/\/CRAN.R-project.org\/package=blockrand."},{"key":"4467_CR23","doi-asserted-by":"crossref","unstructured":"Vanderweele TJ. Explanation in causal inference. Methods for mediation and interaction. New York: Oxford University Press; 2015.","DOI":"10.1093\/ije\/dyw277"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-020-04467-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T19:23:52Z","timestamp":1623785032000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04467-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,16]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04467-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-15451\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-15451\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,16]]},"assertion":[{"value":"21 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was reviewed and approved by the RUSVM Institutional Review Board (protocol 18\u201304-FL) and the Interim Ethics Review Committee of the Ministry of Health, St. Kitts and Nevis (approval code IERC-2019-11-032). Written informed consent is obtained from all participants prior to their enrollment in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"In the informed consent document, participants provide consent to the following statement on publication, \u201cYour information will be combined with information from other people taking part in the study. When we write about the study to share it with other researchers, we will write about the combined information we have gathered. You will not be personally identified in these written materials. We may publish the results of this study; however, we will keep your name and other identifying information private.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"BDG worked for Agence de M\u00e9decine Pr\u00e9ventive (AMP) through 2017 and currently advises the company. AMP has received grant support from Sanofi Pasteur, a manufacturer of rabies vaccine. BDG currently serves as the Global Medical Lead for Pneumococcal Vaccines at Pfizer, but Pfizer has no role in the current study and Dr. Gessner participates in the current trial outside of his duties with Pfizer. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"534"}}